Deep Learning Magnetic Resonance Imaging Radiomic Predict Platinum-sensitive in Patients With Epithelial Ovarian Cancer

NCT ID: NCT04511481

Last Updated: 2020-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

93 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-15

Study Completion Date

2021-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Platinum-sensitive is an important basis for the treatment of recurrent epithelial ovarian cancer (EOC) without effective methods to predict.We aimed to develop and validate the EOC deep learning system to predict the platinum-sensitive of EOC patients through analysis of enhanced magnetic resonance imaging (MRI) images before initial treatment.Ninety-three EOC patients received platinum-based chemotherapy (\>= 4 cycles) and debulking surgery from Sun Yat-sen Memorial Hospitalin China from January 2011 to January 2020 were enrolled. This deep-learning EOC signature achieved a high predictive power for platinum-sensitive, and the signature based on MRI whole volume is better than that on primary tumor area only.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Predictive Cancer Model

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

platinum-resistant group

Radiomic Algorithm

Intervention Type OTHER

Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction

platinum-sensitive group

Radiomic Algorithm

Intervention Type OTHER

Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiomic Algorithm

Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1)Patients with epithelial ovarian cancer (2 )Patients received platinum-based chemotherapy (\>= 4 cycles) and debulking surgery

Exclusion Criteria

* Patients with epithelial ovarian cancer received less than 4 cycles platinum-based chemotherapy or no debulking surgery
Minimum Eligible Age

22 Years

Maximum Eligible Age

99 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Herui Yao

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sun Yat-Sen Memorial Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ruilin Lei, phD

Role: CONTACT

+8618898325866

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Herui Yao, PhD

Role: primary

+8613500018020

Yunfang Yu, MD

Role: backup

+8613660238987

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SYSEC-KY-KS-2020-072

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.